ArchiMed acquires Zyto Group

The founders and management team of the company will continue to hold a significant minority stake in the business, ArchiMed said in a statement.

Zyto Group has been acquired via the ZytoMax holding company, which comprises the Zytomed Systems, ZytoVision and 42 Life Sciences businesses, according to the same statement.

Following the acquisition, ArchiMed intends to appoint supervisory board members specialised in medtech and tissue diagnostics via its MedTalents network, the GP said in the same statement.

The GP also aims to assist the company with its internationalisation and development of new diagnostic products, including to detect lymphoma and leukemia.

ArchiMed is investing via Med II, which held a final close in 2017 on €315m. The fund deploys equity tickets of €5-50m, making both buyout and growth capital investments in the healthcare sector.

Company
Zyto Group develops, manufactures and distributes cancer diagnostics tests and equipment for use in hospitals, clinics and private practices. The group is headquartered in Berlin and comprises Zytomed Systems, ZytoVision and 42 Life Sciences. Zytomed Systems was founded in 2005.

People
ArchiMed – Vincent Guillaumot (managing partner).
Zyto Group – Kerstin Weyrauch, Sven Hauke (co-founders).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany
• Archimed